GlassScriptPhysician profile
Jagadeesh K Reddy
NPI 1538199104
$6,298.50
in general payments reported to CMS, 2019-2025
31 companies · $645 in 2025
The $645 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,168 · 2020: $862 · 2021: $1,157 · 2022: $702 · 2023: $846 · 2024: $919 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,410.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,321.53 | 2019-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $947.98 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $685.80 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $491.42 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $401.94 | 2019-2022 | |
| Lilly USA, LLC | $376.64 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $324.70 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.42 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $179.46 | 2023-2025 | |
| Bausch Health US, LLC | $179.39 | 2019-2022 | |
| Eisai INC. | $146.15 | 2020-2021 | |
| Pfizer INC. | $144.44 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $112.54 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $95.41 | 2019-2020 | |
| Dexcom, INC. | $94.86 | 2021-2024 | Dexcom G6 Transmitter |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $83.49 | 2019-2023 | Proquad, Vaxneuvance, Vaqta |
| Sanofi-Aventis U.S. LLC | $53.78 | 2019-2021 | |
| Exact Sciences Corporation | $51.07 | 2024-2025 | Cologuard Collection Kit |
| Lundbeck LLC | $49.14 | 2024-2025 | Rexulti |
| Genentech USA, INC. | $48.72 | 2019-2020 | |
| Hologic Sales and Service, LLC | $40.70 | 2024 | Aptima, Thinprep 2000 Processor |
| Otsuka America Pharmaceutical, INC. | $39.62 | 2023 | Rexulti, Nuedexta |
| Avanir Pharmaceuticals, INC. | $34.89 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $33.38 | 2023-2024 | Linzess |
| Abbott Laboratories | $28.37 | 2024 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $27.00 | 2022 | |
| Allergan, INC. | $25.74 | 2020 | |
| Philips North America LLC | $22.92 | 2019 | |
| Abbvie INC. | $20.85 | 2022 | |
| Idorsia Pharmaceuticals US INC | $20.83 | 2023 | Quviviq |
| Medtronic USA, INC. | $13.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jagadeesh Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.